The objective of this study is to assess the reproducibility of PAXG regimen as
first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal
Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a
large volume center.